Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

References

• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood200811152516252017975015
   PubMed Web of Science ®Google Scholar
• RockKLGrammCRothsteinLInhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I moleculesCell19947857617718087844
   PubMed Web of Science ®Google Scholar
• AdamsJThe proteasome: a suitable antineoplastic targetNat Rev Cancer20044534936015122206
   PubMed Web of Science ®Google Scholar
• KoeppDMHarperJWElledgeSJHow the cyclin became a cyclin: regulated proteolysis in the cell cycleCell199997443143410338207
   PubMed Web of Science ®Google Scholar
• PanditBGartelALProteasome inhibitors induce p53-independent apoptosis in human cancer cellsAm J Pathol2011178135536021224072
   PubMed Web of Science ®Google Scholar
• ObengEACarlsonLMGutmanDMProteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cellsBlood2006107124907491616507771
   PubMed Web of Science ®Google Scholar
• PivaRRuggeriBWilliamsMCEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomibBlood200811152765277518057228
   PubMed Web of Science ®Google Scholar
• ZhouHJAujayMABennettMKDesign and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)J Med Chem20095293028303819348473
   PubMed Web of Science ®Google Scholar
• PottsBCAlbitarMXAndersonKCMarizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsCurr Cancer Drug Targets201111325428421247382
   PubMed Web of Science ®Google Scholar
• KuhnDJChenQVoorheesPMPotent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood200711093281329017591945
   PubMed Web of Science ®Google Scholar
• BianchiGOlivaLCascioPThe proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibitionBlood2009113133040304919164601
   PubMed Web of Science ®Google Scholar
• OerlemansRFrankeNEAssarafYGMolecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 proteinBlood200811262489249918565852
   PubMed Web of Science ®Google Scholar
• RuckrichTKrausMGogelJCharacterization of the ubiquitin-proteasome system in bortezomib-adapted cellsLeukemia20092361098110519225532
   PubMed Web of Science ®Google Scholar
• SuzukiEDemoSArastu-KapurSBortezomib-resistant cell lines have increased proteasome levels but remain sensitive to carfilzomibASH Annual Meeting Abstracts200911422Abstr: 2852
   Google Scholar
• O’ConnorOAStewartAKValloneMA phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignanciesClin Cancer Res200915227085709119903785
   PubMed Web of Science ®Google Scholar
• AlsinaMTrudelSValloneMPhase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignanciesASH Annual Meeting Abstracts200711011Abstr: 411
   Google Scholar
• JagannathSVijRStewartKFinal results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)J Clin Oncol200927Suppl 15sAbstr 8504
   Google Scholar
• diCapua SiegelDSMartinTWangMResults of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)ASH Annual Meeting Abstracts201011621Abstr: 985
   Google Scholar
• VijRWangMKaufmanJLAn open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaBlood2012
   Web of Science ®Google Scholar
• VijRSiegelDSKaufmanJLResults of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM)J Clin Oncol201028Suppl 15sAbstr 8000
   Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• OrlowskiRZNaglerASonneveldPRandomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionJ Clin Oncol200725253892390117679727
   PubMed Web of Science ®Google Scholar
• WangLSiegelDSJakubowiakAJThe speed of response to single- agent carfilzomib in patients with relapsed and/or refractory multiple myeloma: an exploratory analysis of results from 2 multicenter phase 2 clinical trialsASH Annual Meeting Abstracts201111821Abstr: 3969
   Google Scholar
• DemoSDKirkCJAujayMAAntitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeCancer Res200767136383639117616698
   PubMed Web of Science ®Google Scholar
• SquiffletPMichielsSSiegelDSMultivariate modelling reveals evidence of a dose-response relationship in phase 2 studies of single-agent carfilzomibASH Annual Meeting Abstracts201111821Abstr: 1877
   Google Scholar
• PapadopoulosKPLeePSinghalSA Phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007ASH Annual Meeting Abstracts201111821Abstr: 2930
   Google Scholar
• JakubowiakAJSiegelDSSinghalSUnfavorable cytogenetic characteristics do not adversely impact response rates in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib on the 003 (A1) studyASH Annual Meeting Abstracts201111821Abstr: 1875
   Google Scholar
• BadrosAZVijRMartinTPhase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiencyJ Clin Oncol201028Suppl 15sAbstr: 8128
   Web of Science ®Google Scholar
• SinghalSSiegelDSMartinTIntegrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysisASH Annual Meeting Abstracts201111821Abstr: 1876
   Google Scholar
• JagannathSVijRKaufmanJLLong-term treatment and tolerability of the novel proteasome inhibitor carfilzomib (CFZ) in patients with relapsed and/or refractory multiple myeloma (R/R MM)ASH Annual Meeting Abstracts201011621Abstr: 1953
   Google Scholar
• Arastu-KapurSAnderlJLKrausMNonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse eventsClin Cancer Res20111792734274321364033
   PubMed Web of Science ®Google Scholar
• JagannathSJVijRVMartinTMBadrosABPatelPPMcCullochLMCarfilzomib is associated with a low rate of typically mild to moderate, non-dose limiting treatment-emergent peripheral neuropathyEuropean Hematological Association Annual Meeting2012AmsterdamAbstr: 0857
   Google Scholar
• BensingerWWangMOrlowskiRZDose-escalation study of carf ilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM)J Clin Oncol201028158029
   Web of Science ®Google Scholar
• MoreauPPalumboAStewartAKA randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM)J Clin Oncol20112915TPS225
   Web of Science ®Google Scholar
• KisselevAFvan der LindenWAOverkleeftHSProteasome inhibitors: an expanding army attacking a unique targetChem Biol20121919911522284358
   PubMed Web of Science ®Google Scholar
• SuzukiEDemoSDeuEMolecular mechanisms of bortezomib-resistant adenocarcinoma cellsPLoS One2011612e2799622216088
   PubMed Web of Science ®Google Scholar
• LuSYangJSongXPoint mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/ leukemia lineJ Pharmacol Exp Ther2008326242343118502982
   PubMed Web of Science ®Google Scholar
• LuSYangJChenZDifferent mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell lineExp Hematol200937783183719426847
   PubMed Web of Science ®Google Scholar
• RiMIidaSNakashimaTBortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stressLeukemia20102481506151220555361
   PubMed Web of Science ®Google Scholar